BackgroundOsteoporosis is a chronic, progressive, systemic condition of the skeletal tissue that is characterized by reduced bone density, microarchitecture deterioration, and fragile bones, making osteoporotic fractures or fragility fractures more likely to occur. This condition often remains asymptomatic and undiagnosed until it presents with fragility fractures. The condition is associated with a significant socioeconomic burden with disability, morbidity, and mortality. Therefore, early diagnosis, as well as treatment, is needed to prevent fractures. Intravenous zoledronic is an effective bisphosphonate with high patient compliance due to onceyearly dosing. The present study aims to determine whether zoledronic acid effectively treats chronic back pain in people with osteoporosis. Materials and methodsSeventy patients above the age of 60 years presented with complaints of chronic low back aches to the outpatient department of orthopedics, R L Jalappa Hospital & Research Centre attached to Sri Devaraj Urs Medical College. The study was conducted between November 2016 and November 2018. ResultsAll the patients found excellent clinical improvement following zoledronic acid infusion in early and longterm follow-ups. Additionally, it was found that zoledronic acid's effectiveness was excellent, with significant improvement in bone mineral density (BMD), T-score, and Z-score. ConclusionEarly diagnosis and treatment of vertebral osteoporosis is the most important factor in preventing fragility fractures. Zoledronic acid, an antiresorptive drug with better compliance, is very effective in controlling low back pain, improving bone mineral density, and preventing the occurrence of atraumatic fragility fractures. With all the above factors, zoledronic acid is a preferable bisphosphonate for the treatment and prevention of osteoporosis compared to other modalities of treatment of osteoporosis.

BackgroundDistal end radius fractures (DRF), which account for 17.5% of all fractures, are the most frequent fracture seen in emergency rooms. In patients with DRFs, delayed carpal tunnel syndrome (CTS) occurs in about 20% of cases. When patients are treated with DRFs using different modalities, CTS results in poor functional outcomes. Our study aims to identify the prevalence of CTS in DRF patients receiving treatment with various modalities. Materials and methodsTwo hundred twenty patients with a history of DRFs who were treated by a variety of modalities at R.L. Jalappa Hospital and Research Center between January 2013 and January 2018 are included in this retrospective analysis. The medical records from the department of the hospital's paperwork were used to gather the patient's information and radiographs. The information was gathered, tabulated, and examined. ResultsIn our study, the incidence of CTS in DRF was calculated using a sample size of 220 and found to be 32.73%. The incidence of CTS was shown to be higher in groups with more comminution than less comminution when treatment modalities were analyzed. These groups included closed reduction and internal fixation (CRIF)/open reduction and internal fixation (ORIF) with K wire, external fixation, conservative with the cast, ORIF with variable angle volar locking plate (VAVLP), and ORIF with volar T locking plates (VTLP). ConclusionsAfter DRFs, carpal tunnel syndrome is the most significant consequence limiting functional results, hence preventing it requires considerably more attention and care.